What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2020-11-03 compared with 2020-08-05 · 90 added, 87 removed, 181 unchanged (49% of the section changed)

6 unchanged sentences

Owens & Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading global healthcare solutions company.

On June 18, 2020 (the Divestiture Date), we completed the previously announced divestiture of our European logistics business, Movianto (the Divestiture), as well as certain support functions in our Dublin office, to Walden Group SAS (the Buyer) and EHDH (as Buyer’s guarantor) for cash consideration of $133 million.

On June 18, 2020 (the Divestiture Date), we completed the previously announced divestiture of our European logistics business, Movianto (the Divestiture), as well as certain support functions in our Dublin, Ireland office, to Walden Group SAS (the Buyer) and EHDH (as Buyer’s guarantor) for cash consideration of $133 million.

The Divestiture provides us with a greater ability to focus on and invest in our di fferentiated products, services and U.S.

1 unchanged sentence

A portion of the net proceeds was used to repurchase $54.1 million of our 2021 Notes through a tender offer (see Note 6, “Debt”).

We recorded losses of $56.4 million and $65.5 million, respectively, in connection with the Divestiture for the three and six months ended June 30, 2020.

We recorded a loss of $65.5 million in connection with the Divestiture for the nine months ended September 30, 2020.

We have entered into transition services agreements with a subsidiary of the Buyer, pursuant to which we and a subsidiary of the B uyer will provide to each other various transitional services.

Transition service expenses and reimbursements were immaterial for the three and six months ended June 30, 2020.

Transition service expenses and reimbursements were immaterial for the three and nine months ended September 30, 2020.

As a result of the Divestiture, the results of operations from our Movianto business are reported as “Loss from discontinued operations, net of tax” through the Divestiture Date and the related assets and liabilities were classified as “held-for-sale” in the consolidated balance sheet as of December 31, 2019.

1 unchanged sentence

Unless otherwise indicated, the following information relates to continuing operations.

Income (loss) from continuing operations per diluted share was $0.00 and $(0.14) for the three and six months ended June 30, 2020, respectively, as compared to $(0.16) and $(0.34) for the three and six months ended June 30, 2019, respectively.

Global Solutions segment operating loss was $(10.1) million and $(2.5) million for the three and six months ended June 30, 2020, respectively, compared to operating income of $17.7 million and $39.4 million for the three and six months ended June 30, 2019, respectively.

Income (loss) from continuing operations per diluted share was $0.76 and $0.61 for the three and nine months ended September 30, 2020, respectively, as compared to $0.06 and $(0.28) for the three and nine months ended September 30, 2019, respectively.

Global Solutions segment operating income was $11.0 million and $8.5 million for the three and nine months ended September 30, 2020, respectively, compared to $24.9 million and $64.3 million for the three and nine months ended September 30, 2019, respectively.

The declines were a result of lower revenues in part from a reduction in elective surgeries as compared to prior year.

Global Products segment operating income was $51.8 million and $70.3 million for the three and six months ended June 30, 2020, respectively, compared to $17.9 million and $25.7 million for the three and six months ended June 30, 2019, respectively.

Global Products segment operating income was $89.9 million and $160.3 million for the three and nine months ended September 30, 2020, respectively, compared to $16.9 million and $42.6 million for the three and nine months ended September 30, 2019, respectively.

The increases were a result of higher revenues from greater market demand for personal protective equipment and favorable product mix combined with continued operating efficiencies compared to 2019.

3 unchanged sentences

We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state or local authorities or that we determine are in the best interests of our teammates, customers, suppliers and shareholders.

T able of Contents

Revenue in the first six months of 2020 of $3.9 billion includes a significant overall impact from COVID-19 related to the reduction of surgical procedures beginning in mid-March through the end of the second quarter, which was partially offset by a greater demand for personal protective equipment (PPE).

Revenue in the first nine months of 2020 of $6.1 billion includes a significant overall impact from COVID-19 related to the reduction of surgical procedures beginning in mid-March, which was partially offset by a greater demand for personal protective equipment (PPE).

Operating income also benefited from improved productivity and increased manufacturing output related to PPE, favorable product mix and operating efficiencies.

We have expanded our PPE production operations to 24 hours a day, 7 days a week, and have taken measures to increase and improve our production such as retooling existing equipment, installing and optimizing new production lines and ramping up our new non-woven fabric machinery.

We have delivered nearly 11 billion units of PPE, of which approximately 4 billion units were produced with materials manufactured in our American factories or Owens & Minor owned facilities, since January 2020.

We expect that we will continue servicing our customers' needs related to the heightened demand for our PPE as a result of various factors, including the implementation of new regulations and healthcare protocols calling for increased use of PPE, healthcare professional preference for medical grade PPE, stockpile PPE demand and the creation of new channels for PPE demand in healthcare, non-healthcare and international markets.

We are evaluating various government-sponsored COVID-response stimulus, relief, and production initiatives such as under the Defense Production Act (DPA) and recent Coronavirus Aid, Relief and Economic Security (CARES) Act.

2 unchanged sentences

nature of the agreement provides a program of expedited partial funding to begin expansion while final terms are completed.

Through June 30, 2020, approximately $12 million had been expended and reimbursed in accordance with this arrangement.

In addition, as allowed under the CARES Act, we have filed for a $13 million income tax refund with the IRS related to the carryback of net operating losses (NOL) incurred in 2018.

This refund receivable was included in other current assets on our balance sheet as of June 30, 2020.

In connection with this NOL carryback, we recorded a $5.2 million benefit to the income tax benefit for the six months ended June 30, 2020.

We are unable to predict with certainty the full impact that COVID-19 will have on our future financial position and operating results due to numerous variables.

Through September 30, 2020, approximately $20.4 million had been expended and reimbursed in accordance with this arrangement.

In addition, as allowed under the CARES Act, we filed for $13.0 million and $17.6 million income tax refunds with the Internal Revenue Service (IRS) related to the carryback of net operating losses (NOL) incurred in 2018 and 2019, respectively.

As of September 30, 2020, the $13.0 million refund was received and the $17.6 million refund was included in other current assets on our consolidated balance sheet.

In connection with these NOL carryback items, we recorded a $7.0 million and $12.2 million benefit to the income tax benefit for the three and nine months ended September 30, 2020.

We are unable to predict the length of the pandemic and the full impact that COVID-19 will have on our future financial position and operating results due to numerous variables and continued uncertainties.

Although we have experienced growth in sales volumes for certain of our products (such as PPE) during the COVID-19 pandemic, as well as improved productivity and manufacturing output, there can be no assurance that such growth rates, increased sales volumes or other improvements will be maintained during or following the COVID-19 pandemic.

Results of Operations

Three Months Ended June 30, Change

Three Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

3 unchanged sentences

Net revenue $ 2,187,928 $ 2,292,752 $ (104,824) (4.6) %

Six Months Ended June 30, Change

Nine Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

3 unchanged sentences

Net revenue $ 6,118,340 $ 7,020,296 $ (901,956) (12.8) %

The change in net revenue for the three and six months ended June 30, 2020 reflected the impact of a reduction in elective surgical procedures, primarily due to the impact of COVID-19, and lower distribution revenues as a result of customer non-renewals that occurred in 2019.

These were partially offset by revenue growth in Global Products from increased demand for personal protective equipment and growth in Byram, our Home Healthcare business.

Foreign currency translation had an unfavorable impact on net revenue of $1.5 million and $3.6 million for the three and six months ended June 30, 2020, respectively, as compared to the prior year.

The change in net revenue for the three and nine months ended September 30, 2020 reflected the impact of a reduction in elective surgical procedures, primarily due to the impact of COVID-19, and lower distribution revenues as a result of customer non-renewals that occurred in 2019.

These were partially offset by revenue growth in Global Products from increased demand for PPE and growth in Byram, our Home Healthcare business.

Foreign currency translation had a favorable impact on net revenue of $1.9 million for the three months ended September 30, 2020 and an unfavorable impact on net revenue of $1.7 million for the nine months ended September 30, 2020, as compared to the prior year.

Cost of goods sold.

Three Months Ended June 30, Change

Three Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

Cost of goods sold $ 1,843,589 $ 2,012,130 $ (168,541) (8.4) %

T able of Contents

Six Months Ended June 30, Change

Nine Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

6 unchanged sentences

Gross margin.

Three Months Ended June 30, Change

Three Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

1 unchanged sentence

As a % of net revenue 15.74 % 12.24 %

Six Months Ended June 30, Change

Nine Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

1 unchanged sentence

As a % of net revenue 14.42 % 12.02 %

Gross margin in the three and six months ended June 30, 2020 were impacted by lower distribution revenues and unfavorable impact from foreign currency translation of $1.4 million and $4.2 million, respectively.

The increase in gross margin as a percentage of revenue reflected an improved sales mix and productivity and operating efficiencies in Global Products.

Gross margin in the three and nine months ended September 30, 2020 were impacted by improved sales mix and productivity, operating efficiencies in Global Products and a favorable impact from foreign currency translation of $5.4 million and $1.1 million, respectively.

Operating expenses.

Three Months Ended June 30, Change

Three Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

3 unchanged sentences

Other operating (income) expense, net $ (134) $ 1,329 $ (1,463) (110.1) %

Six Months Ended June 30, Change

Nine Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

5 unchanged sentences

Shipping and handling costs are primarily included in DS&A expenses and include costs to store, move, and prepare products for shipment, as well as costs to deliver products to customers.

T able of Contents

Overall DS&A expenses were affected by the revenue decline and change in mix and investments in the business, partially offset by operational efficiencies.

DS&A expenses also included favorable impacts for foreign currency translation of $0.3 million and $0.6 million for the three and six months ended June 30, 2020, respectively.

Acquisition-related charges were $3.9 million and $8.1 million for the three and six months ended June 30, 2020,

compared to $3.7 million and $7.8 million for the same periods of 2019.

DS&A expenses also included an unfavorable impact for foreign currency translation of $0.3 million for the three months ended September 30, 2020 and a favorable impact for foreign currency translation of $0.3 million for the nine months ended September 30, 2020.

Acquisition-related charges were $0.8 million and $8.9 million for the three and nine months ended September 30, 2020, compared to $3.5 million and $11.4 million for the same periods of 2019.

Acquisition-related charges in 2020 and 2019 consist primarily of transition costs for the Halyard acquisition.

Exit and realignment charges were $2.2 million and $4.0 million for the three and six months ended June 30, 2020, compared to $1.7 million and $2.4 million for the same periods of 2019.

Amounts in 2020 were associated with severance from reduction in force and other costs related to the reorganization of the U.S.

Exit and realignment charges were $5.6 million and $9.6 million for the three and nine months ended September 30, 2020, compared to $1.0 million and $3.4 million for the same periods of 2019.

Amounts in 2020 were associated with severance from reduction in force, post divestiture costs related to the Movianto business and other costs related to the reorganization of the U.S.

commercial, operations and executive teams.

4 unchanged sentences

Interest expense, net .

Three Months Ended June 30, Change

Three Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

1 unchanged sentence

Effective interest rate 5.64 % 6.04 %

Six Months Ended June 30, Change

Nine Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

1 unchanged sentence

Effective interest rate 6.35 % 7.38 %

Interest expense for the three and six months ended June 30, 2020 decreased primarily due to a reduction in debt and a decrease in our effective interest rate, which were partially offset by the amortization of additional deferred financing costs as a result of the Fifth Amendment to the Credit Agreement in February 2020.

Interest expense, net for the three and nine months ended September 30, 2020 decreased primarily due to a reduction in debt and a decrease in our effective interest rate, which were partially offset by the amortization of additional deferred financing costs as a result of the Fifth Amendment to the Credit Agreement in February 2020.

See Note 6 in Notes to Consolidated Financial Statements.

Other (income) expense, net .

Three Months Ended June 30, Change

Other expense, net .

Three Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

Other (income) expense, net $ (4,552) $ 731 $ (5,283) (722.7) %

Six Months Ended June 30, Change

Other expense, net $ 1,093 $ 550 $ 543 98.7 %

Nine Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

Other expense, net $ 1,387 $ 4,014 $ (2,627) (65.4) %

Other (income) expense, net for the three months ended June 30, 2020 includes a gain from the surrender of company-owned life insurance policies and gain on extinguishment of debt related to the partial repurchase of our 2024 Notes, which was partially offset by the write-off of deferred financing costs, third party fees incurred, and interest cost and net actuarial losses related to the U.S.

Other expense, net for the three months ended September 30, 2020 and September 30, 2019 primarily relate to interest cost and net actuarial losses related to the U.S.

Retirement Plan.

Other expense, net for the six months ended June 30, 2020 includes the write-off of deferred financing costs, third party fees incurred, and interest cost and net actuarial losses related to the U.S.

Other expense, net for the nine months ended September 30, 2020 includes the write-off of deferred financing costs, third party fees incurred, and interest cost and net actuarial losses related to the U.S.

Retirement Plan, offset by a gain from the surrender of company-owned life insurance policies and gain on extinguishment of debt related to the partial repurchase of our 2021 and 2024 Notes.

Other (income) expense, net for the three and six months ended June 30, 2019 includes interest cost and net actuarial losses related to the U.S.

Retirement Plan and the write-off of deferred financing costs.

T able of Contents

Other expense, net for the nine months ended September 30, 2019 includes interest cost and net actuarial losses related to the U.S.

Retirement Plan, the write-off of deferred financing costs associated with the revolving credit facility as a result of the Fourth Amendment to the Credit Agreement in February 2019, and gain on extinguishment of debt related to the partial repurchase of our 2021 Notes.

Income taxes.

Three Months Ended June 30, Change

Three Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

1 unchanged sentence

Effective tax rate 13.8 % -126.5 %

Six Months Ended June 30, Change

Nine Months Ended September 30, Change

(Dollars in thousands) 2020 2019 $ %

Income tax benefit $ (3,541) (1,816) $ (1,725) (95.0) %

Income tax provision (benefit) $ 3,863 (3,726) $ 7,589 203.7 %

Effective tax rate 9.4 % 17.8 %

The change in the effective tax rates compared to 2019 resulted from an income tax benefit recorded in the first quarter of 2020 associated with the Coronavirus Aid, Relief, and Economic Security (CARES) Act, the mixture of income and losses in jurisdictions in which we operate, and the incremental income tax expense associated with the vesting of restricted stock.

The change in the effective tax rates compared to 2019 resulted primarily from an income tax benefit recorded in the first and third quarters of 2020 associated with the Coronavirus Aid, Relief, and Economic Security (CARES) Act, year over year changes in, and mixture of, income and losses in jurisdictions in which we operate, and the incremental income tax expense associated with the vesting of restricted stock.

In addition, the provision for income taxes reflects an increase in our reserve for uncertain tax positions for the three and nine months ended September 30, 2020 in connection with the IRS’ audit of our 2015 and 2016 consolidated income tax returns described in Note 9 in the Notes to Consolidated Financial Statements.

Financial Condition, Liquidity and Capital Resources

4 unchanged sentences

Changes in our working capital can vary in the normal course of business based upon the timing of inventory purchases, collections of accounts receivable, and payments to suppliers.

June 30, 2020 December 31, 2019 Change

September 30, 2020 December 31, 2019 Change

(Dollars in thousands) $ %

6 unchanged sentences

(1) Based on period end accounts receivable and net revenue for the quarter

(2) Based on average inventory and annualized costs of goods sold for the quarter ended June 30, 2020 and year ended December 31, 2019

(2) Based on average inventory and annualized costs of goods sold for the quarter ended September 30, 2020 and year ended December 31, 2019

Liquidity and capital expenditures.

The following table summarizes our consolidated statements of cash flows for the six months ended June 30, 2020 and 2019, which relates to continuing operations and discontinued operations:

The following table summarizes our consolidated statements of cash flows for the nine months ended September 30, 2020 and 2019, which relates to continuing operations and discontinued operations:

(Dollars in thousands) 2020 2019

4 unchanged sentences

Effect of exchange rate changes 6,721 (2,243)

Net increase (decrease) in cash, cash equivalents and restricted cash $ 111,766 $ (12,028)

Cash provided by operating activities in the first six months of 2020 reflected fluctuations in net income along with favorable changes in working capital.

T able of Contents

Cash provided by investing activities in the first six months of 2020 included cash consideration received of $133.0 million from the sale of Movianto, proceeds of $6.0 million from the surrender of company-owned life insurance policies, and capital expenditures of $12.1 million for our strategic and operational efficiency initiatives associated with property and equipment, investments for increased manufacturing capacity in the Americas, and capitalized software.

Net increase in cash, cash equivalents and restricted cash $ 142,792 $ 9,636

Cash provided by operating activities in the first nine months of 2020 reflected fluctuations in net income along with favorable changes in working capital.

Cash provided by investing activities in the first nine months of 2020 included cash consideration received of $133.0 million from the sale of Movianto, proceeds of $6.0 million from the surrender of company-owned life insurance policies, and capital expenditures of $26.4 million for our strategic and operational efficiency initiatives associated with property and equipment, investments for increased manufacturing capacity in the Americas, and capitalized software.

Cash used for investing activities in 2019 included capital expenditures for our strategic and operational efficiency initiatives associated with property and equipment and capitalized software.

Cash used for financing activities in the first six months of 2020 included dividend payments of $0.3 million and repayments of $47.9 million under our revolving credit facility, compared to dividend payments of $4.9 million and proceeds from borrowings of $19.9 million for the same period of 2019.

We also had proceeds from borrowings of $150.0 million related to the Accounts Receivable Securitization Program.

Financing activities also included repayments of $258.0 million in the first six months of 2020 compared to $24.8 million in the same period of 2019 on our term loans (under the Credit Agreement) and 2021 Notes and 2024 Notes.

We used $83.2 million of cash to repurchase $87.8 million aggregate principal amount of the 2021 and 2024 Notes during the first six months of 2020.

We als o paid $10.4 million in financing costs related to the February 2020 Accounts Receivable Securitization Program and the Fifth Amendment to the February 2020 Credit Agreement, as compared to $4.3 million in financing costs related to the February 2019 Fourth Amendment to the Credit Agreement.

Cash used for financing activities in the first nine months of 2020 included dividend payments of $0.5 million and repayments of $107.9 million under our revolving credit facility, compared to $5.1 million and $36.1 million, respectively, for the same period of 2019.

We also had proceeds from borrowings of $150.0 million related to the Accounts Receivable Securitization Program in the first nine months of 2020.

Financing activities also included repayments of $270.4 million in the first nine months of 2020 compared to $40.7 million in the same period of 2019 on our term loans (under the Credit Agreement) and 2021 and 2024 Notes.

We used $83.3 million of cash to repurchase $87.9 million aggregate principal amount of the 2021 and 2024 Notes during the first nine months of 2020.

We also paid $10.4 million in financing costs related to the February 2020 Accounts Receivable Securitization Program and the February 2020 Fifth Amendment to the Credit Agreement, as compared to $4.3 million in financing costs related to the February 2019 Fourth Amendment to the Credit Agreement.

Capital resources .

Our sources of liquidity include cash and cash equivalents and a revolving credit facility under our Credit Agreement with Wells Fargo Bank, N.A., JPMorgan Chase Bank, N.A., Bank of America, N.A.

and a syndicate of financial institutions (the Credit Agreement).

The Credit Agreement provides a revolving borrowing capacity of $400 million and $686 million in outstanding term loans.

Our sources of liquidity include cash and cash equivalents, a revolving credit facility under our Credit Agreement with Bank of America, N.A, JPMorgan Chase Bank, N.A., Wells Fargo Bank, N.A., and a syndicate of lenders (the Credit Agreement), and the Receivables Securitization Program.

The Credit Agreement provides a revolving borrowing capacity of $400 million.

The interest rate on our revolving credit facility and Term A Loans is based on 1) either the Eurocurrency Rate or the Base Rate plus 2) an Applicable Percentage which varies depending on Consolidated Total Leverage Ratio (each as defined in the Credit Agreement).

Our credit spread on the revolving credit facility and Term A Loans at June 30, 2020 was Eurocurrency Rate plus 4.25%.

Our credit spread on the revolving credit facility and Term A Loans at September 30, 2020 was Eurocurrency Rate plus 4.25%.

Our Term B Loan accrues interest based on 1) either the Eurocurrency Rate or the Base Rate plus 2) an Applicable Percentage of 3.50% per annum for Base Rate Loans, and 4.50% per annum for Eurocurrency Rate Loans (each as defined in the Credit Agreement).

Our credit spread on the Term B Loan at June 30, 2020 was Eurocurrency Rate plus 4.50%.

Our credit spread on the Term B Loan at September 30, 2020 was Eurocurrency Rate plus 4.50% .

We are charged a commitment fee of between 12.5 and 25.0 basis points on the unused portion of the revolving credit facility.

At June 30, 2020 and December 31, 2019, we had borrowings of $130.0 million and $177.9 million, respectively, under the revolver and letters of credit of $13.9 million and $11.7 million, respectively, outstanding under the Credit Agreement.

At June 30, 2020 and December 31, 2019, we had $256.1 million and $209.3 million, respectively, available for borrowing.

At September 30, 2020 and December 31, 2019, we had borrowings of $70.0 million and $177.9 million, respectively, under the revolver and letters of credit of $13.9 million and $11.7 million, respectively, outstanding under the Credit Agreement.

At September 30, 2020 and December 31, 2019, we had $316.1 million and $209.3 million, respectively, available for borrowing.

The December 31, 2019 availability reflected letters of credit associated with discontinued operations of $1.1 million.

There were no letters of credit associated with discontinued operations as of June 30, 2020.

We also had letters of credit and bank guarantees outstanding for $3.6 million, of which $2.0 million are in process of being transferred to the buyer of Movianto, and $1.5 million as of June 30, 2020 and December 31, 2019, respectively, which supports certain leased facilities as well as other normal business activities in the United States and Europe.

There were no letters of credit associated with discontinued operations as of September 30, 2020.

We also had letters of credit and bank guarantees outstanding for $2.4 million, of which $0.8 million are in process of being transferred to the buyer of Movianto, and $1.6 million and $1.5 million as of September 30, 2020 and December 31, 2019, respectively, which supports certain leased facilities as well as other normal business activities in the United States and Europe.

These letters of credit and guarantees were issued independent of the Credit Agreement .

10 unchanged sentences

The Receivables Securitization Program matures on February 17, 2023.

In February 2020, we drew $150 million from the Receivables

T able of Contents

Securitization Program to repay portions of the Term A Loans, consistent with the terms of the Fifth Amendment to the Credit Agreement.

The Fifth Amendment to the Credit Agreement requires that any additional draws on the Receivables Securitization Program are restricted for use to repay the 2021 Notes or Term A loans to the extent those instruments are outstanding.

The Credit Agreement and Senior Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of either agreement.

Our Receivables Securitization Program has a “springing maturity date” with respect to the Term A Loans.

If the outstanding balance of the Term A loans have not been paid in full as of the date 91 days prior to the maturity date of the Term A Loans, then the Scheduled Termination Date (as defined in the Receivables Financing Agreement) of the Receivables Securitization Program shall be the date that is 91 days prior to the maturity date of the Term A Loans.

In February 2020, we drew $150 million from the Receivables Securitization Program to repay portions of the Term A Loans, consistent with the terms of the Fifth Amendment to the Credit Agreement.

The Fifth Amendment to the

Credit Agreement requires that any additional draws on the Receivables Securitization Program are restricted for use to repay the 2021 Notes or Term A loans to the extent those instruments are outstanding.

The Credit Agreement, Receivables Securitization Program, and Senior Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of either agreement.

The terms of the Credit Agreement also require the company to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition or divestiture.

We were in compliance with our debt covenants at June 30, 2020.

We were in compliance with our debt covenants at September 30, 2020.

Current maturities include scheduled principal payments within the next 12 months of $44.6 million and $5.0 million for our Term A and Term B Loans, respectively, $1.0 million in short-term finance leases, and $178.5 million related to our 2021 Notes.

In May 2020, we entered into an equity distribution agreement, pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50 million.

We intend to use the net proceeds from the sale of our securities offered by this program for the repayment of indebtedness and/or for general corporate and working capital purpose.

As of June 30, 2020, no shares were issued and $50 million of common stock remained available under the at-the-market equity financing program.

We intend to use the net proceeds from the sale of our securities offered by this program for the repayment of indebtedness and/or for general corporate and working capital purposes.

As of September 30, 2020 no shares were issued and $50 million of common stock remained available under the at-the-market equity financing program.

On October 6, 2020, we completed a follow-on equity offering wherein we sold an aggregate of 8,475,000 shares of our common stock at an offering price of $20.50, resulting in net proceeds to us of approximately $165 million, after deducting expenses relating to the follow-on equity offering, including the underwriters’ discounts and commissions.

Pursuant to the underwriting agreement, we granted the underwriters an option to purchase up to an additional 1,271,250 shares of our common stock, which the underwriters exercised in full.

Inclusive of this exercised option, net proceeds to us were approximately $190 million, after deducting expenses relating to the follow-on equity offering, including the underwriters’ discounts and commissions.

We used the proceeds from the follow-on equity offering to repay the remaining $109 million outstanding balance of Term Loan A-1 at par on October 8, 2020, to repay $52 million of our Term Loan A-2 at par on October 15, 2020, and to repay $30 million of borrowings under the revolving credit facility.

On October 30, 2020, we issued a notice of redemption to redeem all of our outstanding 2021 Notes on November 30, 2020 (the “Redemption Date”).

The redemption price will include accrued and unpaid interest to, but not including, the Redemption Date, and a redemption premium, equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed or (ii) the sum of the present values of the remaining scheduled payments of principal and interest thereon (exclusive of interest accrued to the Redemption Date) discounted to the Redemption Date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 25 basis points.

From time to time, we may enter into transactions to repay, repurchase or redeem our outstanding indebtedness (including by means of open market purchases, privately negotiated repurchases, tender or exchange offers and/or repayments or redemptions pursuant to the debt’s terms).

1 unchanged sentence

We cannot provide any assurance as to if or when we will consummate any such transactions or the terms of any such transaction.

The second quarter dividend of $0.0025 per share was paid in June 2020.

The third quarter dividend of $0.0025 per share was paid in September 2020.

The payment of future dividends remains within the discretion of the Board of Directors and will depend upon our results of operations, financial condition, capital requirements, current and future limitations under our Credit Agreement (as amended) and other factors.

2 unchanged sentences

We earn a portion of our operating income in foreign jurisdictions outside the United States.

Our cash and cash equivalents held by our foreign subsidiaries totaled $66.3 million and $52.9 million at June 30, 2020 and December 31, 2019, respectively.

Our cash and cash equivalents held by our foreign subsidiaries totaled $32.0 million and $52.9 million at September 30, 2020 and December 31, 2019, respectively.

We continue to remain permanently reinvested in our foreign subsidiaries, with the exception of a subsidiary in Thailand.

We have no specific plans to indefinitely reinvest the unremitted earnings of our foreign subsidiary located in Thailand as of June 30, 2020.

We have no specific plans to indefinitely reinvest the unremitted earnings of our foreign subsidiary located in Thailand as of September 30, 2020.

As such, we have recorded withholding tax liabilities that would be incurred upon future distribution to the U.S.

2 unchanged sentences

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see our Annual Report on Form 10-K for the year ended December 31, 2019 and Note 14 in the Notes to Consolidated Financial Statements, included in this Quarterly Report on Form 10-Q for the quarterly period ended on June 30, 2020.

Forward-looking Statements

3 unchanged sentences

• our ability to achieve revenue and operating income goals may be affected by:

COVID-19 related factors, risks and challenges, including among others, the length of time that the pandemic continues, a decrease in revenue ultimately resulting in less cash flow, longer duration in receivables collection, the need to expedite payments to important suppliers may grow, shifts in demand away from certain products we manufacture and distribute, reduced workforces which may be caused by, but not limited to, the temporary inability of the workforce to work due to illness, quarantine, or government mandates, or temporary production and distribution center and office

T able of Contents

closures due to reduced workforces or government mandates, availability of raw materials, potential resulting labor negotiations or disputes, changes in the types and numbers of businesses that compete with us, including non-traditional competitors, and the aggressiveness of that competition, and trends in elective surgeries and other healthcare spending not directly associated with COVID-19;

COVID-19 related factors, risks and challenges, including among others, the length of time that the pandemic continues, and any worsening of the pandemic or future pandemics, related governmental responses, a decrease in revenue ultimately resulting in less cash flow, longer duration in receivables collection, the need to expedite payments to important suppliers may grow, shifts in demand away from certain products we manufacture and distribute, reduced workforces which may be caused by, but not limited to, the temporary inability of the workforce to work due to illness, quarantine, or government mandates, or temporary production and distribution center and office closures due to reduced workforces or government mandates, availability of raw materials, potential resulting labor negotiations or disputes, changes in the types and numbers of businesses that compete with us, including non-traditional competitors, and the aggressiveness of that competition, impacts of the pandemic or future pandemics on other third parties with whom we conduct business, the healthcare industry, and the broader business environment, and trends in elective surgeries and other healthcare spending not directly associated with COVID-19;

• competitive pressures in the marketplace, including intense pricing pressure;

25 unchanged sentences

and foreign tax laws and the outcome of outstanding tax contingencies and legislative and tax proposals;

T able of Contents

• our ability to successfully implement the expense reduction and productivity and efficiency increasing initiatives;

1 unchanged sentence

• the potentially adverse impact of the United Kingdom’s withdrawal from the European Union;

• other factors detailed from time to time in the reports we file with the SEC.

• other factors detailed from time to time in the reports we file with the SEC, including those described in “Item 1A.

Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019, as updated and supplemented by Item 8.01 of our Current Report on Form 8-K filed with the SEC on March 27, 2020 and our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020.

We undertake no obligation to update or revise any forward-looking statements, except as required by applicable law.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis